Return to Today's science sparks archives

2018-07-02

Fig. 1 Photograph illustrating the different locations of ureteroenteric anastomosis in extracorporeal versus intracorporeal diversion.

Fig. 1 Photograph illustrating the different locations of ureteroenteric anastomosis in extracorporeal versus intracorporeal diversion.
  • Dason S, Goh AC

  • Curr Urol Rep. 2018 Mar 15;19(5):28.

2018-07-03

Figure 2. Cross-Platform Classification Revealed Genomic, Epigenomic, and Transcriptomic Similarities and Differences across Cancer Types.

Figure 2. Cross-Platform Classification Revealed Genomic, Epigenomic, and Transcriptomic Similarities and Differences across Cancer Types.
  • Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Sanchez-Vega F, Robertson AG, Schneider BG, Lawrence MS, Noushmehr H, Malta TM; Cancer Genome Atlas Network, Stuart JM, Benz CC, Laird PW

  • Cell. 2018 Apr 5;173(2):291-304.e6.
Open Access button

2018-07-05

Fig 3. Measurement of the affinity of zefn-A5ECD for mEphA4LBD and zRETECD.

Fig 3. Measurement of the affinity of zefn-A5ECD for mEphA4LBD and zRETECD.
  • Liu Y, Kaljunen H, Pavić A, Saarenpää T, Himanen JP, Nikolov DB, Goldman A

  • PLoS One. 2018 Jun 11;13(6):e0198291.
Open Access button

2018-07-06

Fig 7. ZCCHC8CTD stimulates RNA-dependent ATPase activity of MTR4. Time courses of ATP hydrolysis in the presence or absence of the 3′ A25 tailed RNA duplex.

Fig 7. ZCCHC8CTD stimulates RNA-dependent ATPase activity of MTR4. Time courses of ATP hydrolysis in the presence or absence of the 3′ A25 tailed RNA duplex.
  • Puno MR, Lima CD

  • Proc Natl Acad Sci U S A. 2018 Jun 12;115(24):E5506-E5515.
Open Access button

2018-07-09

Fig 2. Genomic alteration clusters annotated by cell of origin and molecular pathway.

Fig 2. Genomic alteration clusters annotated by cell of origin and molecular pathway.
  • Intlekofer AM, Joffe E, Batlevi CL, Hilden P, He J, Seshan VE, Zelenetz AD, Palomba ML, Moskowitz CH, Portlock C, Straus DJ, Noy A, Horwitz SM, Gerecitano JF, Moskowitz A, Hamlin P, Matasar MJ, Kumar A, van den Brink MR, Knapp KM, Pichardo JD, Nahas MK, Trabucco SE, Mughal T, Copeland AR, Papaemmanuil E, Moarii M, Levine RL, Dogan A, Miller VA, Younes A

  • Blood Cancer J. 2018 Jun 12;8(6):60.
Open Access button

2018-07-10

Fig. 1 Development of patient-derived neuroendocrine prostate cancer models.

Fig. 1 Development of patient-derived neuroendocrine prostate cancer models.
  • Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, Gao D, Cyrta J, Sailer V, Vosoughi A, Pauli C, Churakova Y, Cheung C, Deonarine LD, McNary TJ, Rosati R, Tagawa ST, Nanus DM, Mosquera JM, Sawyers CL, Chen Y, Inghirami G, Rao RA, Grandori C, Elemento O, Sboner A, Demichelis F, Rubin MA, Beltran H

  • Nat Commun. 2018 Jun 19;9(1):2404.
Open Access button

2018-07-11

Fig 4. Electron Densities and Overall Path for RNA

Fig 4. Electron Densities and Overall Path for RNA
  • Weick EM, Puno MR, Januszyk K, Zinder JC, DiMattia MA, Lima CD

  • Cell. 2018 Jun 14;173(7):1663-1677.e21.

2018-07-12

FIGURE 1. Delayed PET/CT-guided biopsy of bone metastasis from prostate carcinoma in 64-
y-old man with strongly suspected metastatic prostate carcinoma (prostatic-specific antigen level, 91 ng/mL), without history of bone radiotherapy.

FIGURE 1. Delayed PET/CT-guided biopsy of bone metastasis from prostate carcinoma in 64- y-old man with strongly suspected metastatic prostate carcinoma (prostatic-specific antigen level, 91 ng/mL), without history of bone radiotherapy.
  • Cornelis FH, Durack JC, Pandit-Taskar N, Ulaner GA, Lewis JS, Morris MJ, Solomon SB

  • J Nucl Med. 2018 Mar;59(3):399-402.

2018-07-13

Fig 2. Time to response and durability of response from the start of therapy in complete responders who discontinued pembrolizumab and proceeded to observation (n = 67). Bar length is equivalent to the time to the last imaging assessment by investigator review. CR, complete response; PD, progressive disease; PR, partial response.

Fig 2. Time to response and durability of response from the start of therapy in complete responders who discontinued pembrolizumab and proceeded to observation (n = 67). Bar length is equivalent to the time to the last imaging assessment by investigator review. CR, complete response; PD, progressive disease; PR, partial response.
  • Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, Hwu WJ, Weber JS, Gangadhar TC, Joseph RW, Dronca R, Patnaik A, Zarour H, Kefford R, Hersey P, Zhang J, Anderson J, Diede SJ, Ebbinghaus S, Hodi FS

  • J Clin Oncol. 2018 Jun 10;36(17):1668-1674.

2018-07-16

Fig. 1 Quantitative imaging workflow for prediction of tumour response.

Fig. 1 Quantitative imaging workflow for prediction of tumour response.
  • Creasy JM, Midya A, Chakraborty J, Adams LB, Gomes C, Gonen M, Seastedt KP, Sutton EJ, Cercek A, Kemeny NE, Shia J, Balachandran VP, Kingham TP, Allen PJ, DeMatteo RP, Jarnagin WR, D'Angelica MI, Do RKG, Simpson AL

  • Eur Radiol. 2018 Jun 19.

2018-07-17

Fig. 1 Pooled CRISPR screening strategies. In a pooled CRISPR screen, a lentiviral sgRNA library is transduced into a cell population at a low multiplicity of infection (MOI) with the goal that each cell receives only one sgRNA integration.

Fig. 1 Pooled CRISPR screening strategies. In a pooled CRISPR screen, a lentiviral sgRNA library is transduced into a cell population at a low multiplicity of infection (MOI) with the goal that each cell receives only one sgRNA integration.
  • Shukla A, Huangfu D

  • Curr Opin Genet Dev. 2018 Jun 15;52:70-76.

2018-07-19

Fig. 1 Table. Assessment of Code From 16 Published Articles.

Fig. 1 Table. Assessment of Code From 16 Published Articles.
  • Assel M, Vickers AJ

  • Ann Intern Med. 2018 Jun 5;168(11):832-833.

2018-07-20

Fig. 1 Somatic genetic alterations identified in 17 ER-negative/HER2-positive and triple-negative breast tumors and matched brain or skin metastases by massively parallel sequencing of 341 cancer-related genes.

Fig. 1 Somatic genetic alterations identified in 17 ER-negative/HER2-positive and triple-negative breast tumors and matched brain or skin metastases by massively parallel sequencing of 341 cancer-related genes.
  • Schrijver WAME, Selenica P, Lee JY, Ng CKY, Burke KA, Piscuoglio S, Berman SH, Reis-Filho JS, Weigelt B, van Diest PJ, Moelans CB

  • Cancer Res. 2018 Jun 15;78(12):3112-3121.

2018-07-23

Fig. 1 Potential reasons for cancer patients' increased risk of ischemic stroke. The diagram depicts the possible underlying explanations for cancer patients' heightened stroke risk.

Fig. 1 Potential reasons for cancer patients' increased risk of ischemic stroke. The diagram depicts the possible underlying explanations for cancer patients' heightened stroke risk.
  • Navi BB, Iadecola C

  • Ann Neurol. 2018 May;83(5):873-883.

2018-07-24

Fig. 1 Thirteen combinations of dose-toxicity and dose-efficacy curves from Yin et al.

Fig. 1 Thirteen combinations of dose-toxicity and dose-efficacy curves from Yin et al.
  • Cunanan KM, Koopmeiners JS

  • Contemp Clin Trials. 2018 Jun 21;71:162-172.

2018-07-25

Fig. 2.1 DSB repair pathways. The two major DSB repair pathways in mammalian cells are nonhomologous end-joining (NHEJ) and homologous recombination (HR).

Fig. 2.1 DSB repair pathways. The two major DSB repair pathways in mammalian cells are nonhomologous end-joining (NHEJ) and homologous recombination (HR).
  • Brunet E, Jasin M

  • Adv Exp Med Biol. 2018;1044:15-25.

2018-07-26

Fig 1. Molecular classes of acute myeloid leukemia (AML) and recurrent gene mutations shows the complexity of the genetics of AML.

Fig 1. Molecular classes of acute myeloid leukemia (AML) and recurrent gene mutations shows the complexity of the genetics of AML.
  • Tallman M

  • J Natl Compr Canc Netw. 2018 May;16(5S):656-659.

2018-07-30

Fig. 2 Cox-2 immunohistochemical staining. Figure contains immunohistochemical staining for Cox-2 showed a wide spectrum of cytoplasmic reactivity ranging from no staining (A), weak staining (B), to diffuse strong staining (C) in the lesional adenoma cells.

Fig. 2 Cox-2 immunohistochemical staining. Figure contains immunohistochemical staining for Cox-2 showed a wide spectrum of cytoplasmic reactivity ranging from no staining (A), weak staining (B), to diffuse strong staining (C) in the lesional adenoma cells.
  • Wang J, Cho NL, Zauber AG, Hsu M, Dawson D, Srivastava A, Mitchell-Richards KA, Markowitz SD, Bertagnolli MM

  • Cancer Epidemiol Biomarkers Prev. 2018 Jul;27(7):728-736.

2018-07-31

Fig. 1 Chimeric Antigen Receptor (CAR) T Cells Engrafting, Trafficking to Tumor, and Proliferating Extensively after Infusion.

Fig. 1 Chimeric Antigen Receptor (CAR) T Cells Engrafting, Trafficking to Tumor, and Proliferating Extensively after Infusion.
  • June CH, Sadelain M

  • N Engl J Med. 2018 Jul 5;379(1):64-73.

2018-08-01

Fig. 1 Antibody-mediated detection of PGRN in tissue or cells by IHC and IF.

Fig. 1 Antibody-mediated detection of PGRN in tissue or cells by IHC and IF.
  • Elkabets M, Brook S

  • Methods Mol Biol. 2018;1806:155-176.

2018-08-02

Fig. 1 Fanconi triple assessment: patients being evaluated for FA require a triple assessment, including (A) history/physical examination, (B) clastogenic testing or chromosomal breakage testing with diepoxybutane ± mitomycin C, and (C) genetic testing.

Fig. 1 Fanconi triple assessment: patients being evaluated for FA require a triple assessment, including (A) history/physical examination, (B) clastogenic testing or chromosomal breakage testing with diepoxybutane ± mitomycin C, and (C) genetic testing.
  • Savage SA, Walsh MF

  • Hematol Oncol Clin North Am. 2018 Aug;32(4):657-668.

2018-08-03

Fig. 1 Plane of capsular dissection (dotted line) during thyroidectomy, dividing vasculature medial (distal) to the parathyroid glands in order to allow preservation of the parathyroid blood supply.

Fig. 1 Plane of capsular dissection (dotted line) during thyroidectomy, dividing vasculature medial (distal) to the parathyroid glands in order to allow preservation of the parathyroid blood supply.
  • Orloff LA, Wiseman SM, Bernet VJ, Fahey TJ 3rd, Shaha AR, Shindo ML, Snyder SK, Stack BC Jr, Sunwoo JB, Wang MB

  • Thyroid. 2018 Jul;28(7):830-841.

2018-08-06

Fig. 1 Copy number loss of KDM5D in PC.

Fig. 1 Copy number loss of KDM5D in PC.
  • Komura K, Yoshikawa Y, Shimamura T, Chakraborty G, Gerke TA, Hinohara K, Chadalavada K, Jeong SH, Armenia J, Du SY, Mazzu YZ, Taniguchi K, Ibuki N, Meyer CA, Nanjangud GJ, Inamoto T, Lee GM, Mucci LA, Azuma H, Sweeney CJ, Kantoff PW

  • J Clin Invest. 2018 Jun 4. pii: 96769.

2018-08-07

Fig. 2 Force types and force screen.

Fig. 2 Force types and force screen.
  • Manhart A, Windner S, Baylies M, Mogilner A

  • PLoS Comput Biol. 2018 Jun 11;14(6):e1006208.
Open Access button

2018-08-08

Fig. 1 Stimulation of BV-2 cells with rHIgM22 promotes myelin phagocytosis.

Fig. 1 Stimulation of BV-2 cells with rHIgM22 promotes myelin phagocytosis.
  • Zorina Y, Stricker J, Caggiano AO, Button DC

  • Sci Rep. 2018 Jun 20;8(1):9392.
Open Access button

2018-08-09

Figure 4. Repeat Element Expression Is a Predictor of Colon Tumor Immune Infiltration and Patient Survival.

Figure 4. Repeat Element Expression Is a Predictor of Colon Tumor Immune Infiltration and Patient Survival.
  • Solovyov A, Vabret N, Arora KS, Snyder A, Funt SA, Bajorin DF, Rosenberg JE, Bhardwaj N, Ting DT, Greenbaum BD

  • Cell Rep. 2018 Apr 10;23(2):512-521.

2018-08-10

Fig. 1 Greater 18F-fluciclovine avidity than 18F-FDG avidity in a patient with a right breast ILC.

Fig. 1 Greater 18F-fluciclovine avidity than 18F-FDG avidity in a patient with a right breast ILC.
  • Ulaner GA, Schuster DM

  • PET Clin. 2018 Jul;13(3):437-444.

2018-08-13

Fig. 1 Adaptive biomarker trial design.

Fig. 1 Adaptive biomarker trial design.
  • Ascierto PA, Puzanov I, Agarwala SS, Bifulco C, Botti G, Caracò C, Ciliberto G, Davies MA, Dummer R, Ferrone S, Gajewski TF, Garbe C, Luke JJ, Marincola FM, Masucci G, Mehnert JM, Mozzillo N, Palmieri G, Postow MA, Schoenberger SP, Wang E, Thurin M

  • J Transl Med. 2018 Jul 21;16(1):207.
Open Access button

2018-08-14

Fig. 1 Venn diagram of fatigue, pain severity and insomnia.

Fig. 1 Venn diagram of fatigue, pain severity and insomnia.
  • Mao H, Bao T, Shen X, Li Q, Seluzicki C, Im EO, Mao JJ

  • Eur J Cancer. 2018 Jul 12;101:47-54.

2018-08-15

Fig. 6 Integrative omics analysis of druggability.

Fig. 6 Integrative omics analysis of druggability.
  • Sengupta S, Sun SQ, Huang KL, Oh C, Bailey MH, Varghese R, Wyczalkowski MA, Ning J, Tripathi P, McMichael JF, Johnson KJ, Kandoth C, Welch J, Ma C, Wendl MC, Payne SH, Fenyö D, Townsend RR, Dipersio JF, Chen F, Ding L

  • Genome Med. 2018 Jul 27;10(1):60.
Open Access button

2018-08-16

Fig. 3 Cell-nonautonomous compensation by spared neighbours in response to mosaic blockade of chondrocyte proliferation.

Fig. 3 Cell-nonautonomous compensation by spared neighbours in response to mosaic blockade of chondrocyte proliferation.
  • Roselló-Díez A, Madisen L, Bastide S, Zeng H, Joyner AL

  • PLoS Biol. 2018 Jun 26;16(6):e2005086.
Open Access button

2018-08-17

Fig. 2 Biophysical and biochemical properties of free lysine (Lys) and methyllysine (Kme1/2/3).

Fig. 2 Biophysical and biochemical properties of free lysine (Lys) and methyllysine (Kme1/2/3).
  • Luo M

  • Chem Rev. 2018 Jul 25;118(14):6656-6705.

2018-08-20

Fig. 2 Atrx deficiency modulates mNPC differentiation state.

Fig. 2 Atrx deficiency modulates mNPC differentiation state.
  • Danussi C, Bose P, Parthasarathy PT, Silberman PC, Van Arnam JS, Vitucci M, Tang OY, Heguy A, Wang Y, Chan TA, Riggins GJ, Sulman EP, Lang F, Creighton CJ, Deneen B, Miller CR, Picketts DJ, Kannan K, Huse JT

  • Nat Commun. 2018 Mar 13;9(1):1057.
Open Access button

2018-08-21

Fig. 1 Hedgehog Signaling Pathway.

Fig. 1 Hedgehog Signaling Pathway.
  • Nehal KS, Bichakjian CK

  • N Engl J Med. 2018 Jul 26;379(4):363-374.

2018-08-22

Fig. 1 Best overall response (A), progression-free survival (PFS) (B), and overall survival (OS) (C) in patients with RCC treated with ICI, stratified by use of ATB within 30 days of initiating ICI.

Fig. 1 Best overall response (A), progression-free survival (PFS) (B), and overall survival (OS) (C) in patients with RCC treated with ICI, stratified by use of ATB within 30 days of initiating ICI.
  • Derosa L, Hellmann MD, Spaziano M, Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC, Chaft JE, Rouche JA, Zitvogel L, Zalcman G, Albiges L, Escudier B, Routy B

  • Ann Oncol. 2018 Jun 1;29(6):1437-1444.

2018-08-23

Fig. 3 Pyruvate metabolism in a small ovarian cancer metastasis (Patient 4) after systemic chemotherapy.

Fig. 3 Pyruvate metabolism in a small ovarian cancer metastasis (Patient 4) after systemic chemotherapy.
  • Miloushev VZ, Granlund KL, Boltyanskiy R, Lyashchenko SK, DeAngelis LM, Mellinghoff IK, Brennan CW, Tabar V, Yang TJ, Holodny AI, Sosa RE, Guo YW, Chen AP, Tropp J, Robb F, Keshari KR

  • Cancer Res. 2018 Jul 15;78(14):3755-3760.

2018-08-24

Fig. 1 Targeted mutational burden (TMB) by age.

Fig. 1 Targeted mutational burden (TMB) by age.
  • Alig S, Jurinovic V, Pastore A, Bararia D, Häbe S, Hellmuth JC, Kridel R, Gascoyne R, Schmidt C, Zöllner AK, Buske C, Dreyling M, Unterhalt M, Hiddemann W, Hoster E, Weigert O

  • Haematologica. 2018 Aug;103(8):e364-e367.
Open Access button

2018-08-27

Fig. 1 Chemical structures of all compounds included in this study.

Fig. 1 Chemical structures of all compounds included in this study.
  • Cho A, Eskandari R, Miloushev VZ, Keshari KR

  • J Magn Reson. 2018 Aug 2;295:57-62.

2018-08-28

Fig. 1 Sacral chordoma involving most of the sacrum (yellow arrow).

Fig. 1 Sacral chordoma involving most of the sacrum (yellow arrow).
  • Cheung F, Sandhu JS

  • Curr Urol Rep. 2018 Aug 6;19(9):75.

2018-08-29

Fig. 3 CT scans showing confirmed partial response in one patient (250 mg BID).

Fig. 3 CT scans showing confirmed partial response in one patient (250 mg BID).
  • Hamilton EP, Patel MR, Armstrong AC, Baird RD, Jhaveri K, Hoch M, Klinowska T, Lindemann JPO, Morgan SR, Schiavon G, Weir HM, Im SA

  • Clin Cancer Res. 2018 Aug 1;24(15):3510-3518.

2018-08-30

Fig. 2 Live cell imaging of rucaparib uptake.

Fig. 2 Live cell imaging of rucaparib uptake.
  • Kossatz S, Carney B, Farley C, Weber WA, Drain CM, Reiner T

  • J Nucl Med. 2018 Aug;59(8):1316-1320.

2018-08-31

Fig. 2 Time to Composite Primary End Point by Type of Results Reported

Fig. 2 Time to Composite Primary End Point by Type of Results Reported
  • Qunaj L, Jain RH, Atoria CL, Gennarelli RL, Miller JE, Bach PB

  • JAMA Oncol. 2018 Jul 12;4(7):e180264.

2018-09-04

Fig. 4 A 41-year-old woman with a positive family history.

Fig. 4 A 41-year-old woman with a positive family history.
  • Marino MA, Riedl CC, Bernathova M, Bernhart C, Baltzer PAT, Helbich TH, Pinker K

  • Eur J Radiol. 2018 Sep;106:150-159.

2018-09-05

Fig. 2 Computational pipeline used to derive a set of marker genes, the NET Marker Panel that identifies GEP-NEN/NET disease in the blood.

Fig. 2 Computational pipeline used to derive a set of marker genes, the NET Marker Panel that identifies GEP-NEN/NET disease in the blood.
  • Modlin IM, Kidd M, Malczewska A, Drozdov I, Bodei L, Matar S, Chung KM

  • Endocrinol Metab Clin North Am. 2018 Sep;47(3):485-504.

2018-09-06

Fig. 1 MASTL expression is upregulated in colon cancer. Patients were evaluated by tumor stage and expression levels were compared to expression levels of normal adjacent samples.

Fig. 1 MASTL expression is upregulated in colon cancer. Patients were evaluated by tumor stage and expression levels were compared to expression levels of normal adjacent samples.
  • Uppada SB, Gowrikumar S, Ahmad R, Kumar B, Szeglin B, Chen X, Smith JJ, Batra SK, Singh AB, Dhawan P

  • Mol Cancer. 2018 Aug 1;17(1):111.
Open Access button

2018-09-07

Fig. 2 The impact of changing diagnostic thresholds on screening related overdiagnosis.

Fig. 2 The impact of changing diagnostic thresholds on screening related overdiagnosis.
  • Kale MS, Korenstein D

  • BMJ. 2018 Aug 14;362:k2820.

2018-09-10

Fig. 1 Loss of miR-146a in B cells led to spontaneous GC reactions in aged mice.

Fig. 1 Loss of miR-146a in B cells led to spontaneous GC reactions in aged mice.
  • Cho S, Lee HM, Yu IS, Choi YS, Huang HY, Hashemifar SS, Lin LL, Chen MC, Afanasiev ND, Khan AA, Lin SW, Rudensky AY, Crotty S, Lu LF

  • Nat Commun. 2018 Jul 16;9(1):2757.
Open Access button

2018-09-11

Fig. 1 Likelihood of using a list of best hospitals for cancer surgery and information patients would have wanted to know about hospitals.

Fig. 1 Likelihood of using a list of best hospitals for cancer surgery and information patients would have wanted to know about hospitals.
  • Yang A, Chimonas S, Bach PB, Taylor DJ, Lipitz-Snyderman A

  • J Oncol Pract. 2018 Aug;14(8):e505-e512.

2018-09-12

Fig. 1 Neuroendocrine neoplasm of the ear showing solid and nested pattern with glandular structures.

Fig. 1 Neuroendocrine neoplasm of the ear showing solid and nested pattern with glandular structures.
  • Katabi N

  • Head Neck Pathol. 2018 Sep;12(3):362-366.

2018-09-13

Fig. 1 Flow diagram describing the main components of computational radiomics pipeline in Computational Environment for Radiological Research (CERR).

Fig. 1 Flow diagram describing the main components of computational radiomics pipeline in Computational Environment for Radiological Research (CERR).
  • Apte AP, Iyer A, Crispin-Ortuzar M, Pandya R, van Dijk LV, Spezi E, Thor M, Um H, Veeraraghavan H, Oh JH, Shukla-Dave A, Deasy JO

  • Med Phys. 2018 Aug;45(8):3713-3720.

2018-09-14

Fig. 1 Cohort 1: Oncology patients who were receiving active treatment and presented to urgent care with a Centers for Medicare & Medicaid Services–defined potentially preventable symptom (6,429 urgent care visits).

Fig. 1 Cohort 1: Oncology patients who were receiving active treatment and presented to urgent care with a Centers for Medicare & Medicaid Services–defined potentially preventable symptom (6,429 urgent care visits).
  • Daly B, Nicholas K, Gorenshteyn D, Sokolowski S, Gazit L, Adams L, Matays J, Katzen LL, Chiu YO, Xiao H, Salvaggio R, Baldwin-Medsker A, Chow K, Nelson J, Ross M, Ng KK, Zervoudakis A, Perchick W, Reidy DL, Simon BA, Wagner I

  • J Oncol Pract. 2018 Aug;14(8):e484-e495.

2018-09-17

Fig. 1 Generation of mono-hormonal pancreatic β-like cells through the induction of late-stage pancreatic progenitors (PP2).

Fig. 1 Generation of mono-hormonal pancreatic β-like cells through the induction of late-stage pancreatic progenitors (PP2).
  • Amin S, Cook B, Zhou T, Ghazizadeh Z, Lis R, Zhang T, Khalaj M, Crespo M, Perera M, Xiang JZ, Zhu Z, Tomishima M, Liu C, Naji A, Evans T, Huangfu D, Chen S

  • Nat Commun. 2018 Jul 11;9(1):2681.
Open Access button

2018-09-18

Fig. 3 Unsupervised clustering heat map of genome-wide mRNA expression profiles, using skin samples from 49 MF/SS patients and 3 healthy individuals.

Fig. 3 Unsupervised clustering heat map of genome-wide mRNA expression profiles, using skin samples from 49 MF/SS patients and 3 healthy individuals.
  • Querfeld C, Leung S, Myskowski PL, Curran SA, Goldman DA, Heller G, Wu X, Kil SH, Sharma S, Finn KJ, Horwitz S, Moskowitz A, Mehrara B, Rosen ST, Halpern AC, Young JW

  • Cancer Immunol Res. 2018 Aug;6(8):900-909.

2018-09-19

Fig. 1 Treatment fields for whole-brain radiation therapy.

Fig. 1 Treatment fields for whole-brain radiation therapy.
  • Pinnix CC, Yahalom J, Specht L, Dabaja BS

  • Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):53-58.

2018-09-20

Fig. 1 Tpo-Cre/FR-HrasG12V+/+/p53f/f mice develop anaplastic and poorly differentiated thyroid cancers.

Fig. 1 Tpo-Cre/FR-HrasG12V+/+/p53f/f mice develop anaplastic and poorly differentiated thyroid cancers.
  • Untch BR, Dos Anjos V, Garcia-Rendueles MER, Knauf JA, Krishnamoorthy GP, Saqcena M, Bhanot UK, Socci ND, Ho AL, Ghossein R, Fagin JA

  • Cancer Res. 2018 Aug 15;78(16):4642-4657.

2018-09-21

Fig. 2 Structure of apalutamide.

Fig. 2 Structure of apalutamide.
  • Rathkopf DE, Scher HI

  • Expert Rev Anticancer Ther. 2018 Sep;18(9):823-836.

2018-09-24

Fig. 1 An individual’s unique mutational signature is a record of the types of DNA alterations sustained throughout their lifetime and can be studied to identify unique patterns of etiology-specific alterations, including carcinogens or DNA repair pathway defects, the latter of which can be inherited or acquired during oncogenesis.

Fig. 1 An individual’s unique mutational signature is a record of the types of DNA alterations sustained throughout their lifetime and can be studied to identify unique patterns of etiology-specific alterations, including carcinogens or DNA repair pathway defects, the latter of which can be inherited or acquired during oncogenesis.
  • Ma J, Setton J, Lee NY, Riaz N, Powell SN

  • Nat Commun. 2018 Aug 17;9(1):3292.
Open Access button

2018-09-26

Fig. 1  Chemical structure of FDG-mNP and disruption of cancer cell.

Fig. 1 Chemical structure of FDG-mNP and disruption of cancer cell.
  • Aras O, Pearce G, Watkins AJ, Nurili F, Medine EI, Guldu OK, Tekin V, Wong J, Ma X, Ting R, Unak P, Akin O

  • PLoS One. 2018 Aug 20;13(8):e0202482.
Open Access button

2018-09-28

Fig. 1A 17-year-old boy with cough and posttussive emesis.

Fig. 1A 17-year-old boy with cough and posttussive emesis.
  • Behr G, Mema E, Costa K, Garg A

  • AJR Am J Roentgenol. 2018 Aug;211(2):321-326.